The term "blood clot" began trending in October 2026 mainly because Philadelphia Eagles quarterback Jalen Hurts was diagnosed with a deep vein thrombosis (DVT), a clot that forms in a deep vein, along with bilateral pulmonary emboli, which are clots that have traveled to both lungs. According to NFL.com, the team and his agent Nicole Lynn stated on Oct. 19 that Hurts is clinically stable, has no significant functional limitations, and will be treated with anticoagulation medication alone. Time.com reported that he is expected to miss the rest of the 2026 season, that recovery is expected to take about three months, and that he cannot take part in contact activities while on blood thinners. The news drove a large public search spike because a high-profile athlete's season-ending illness makes a common but little-understood condition suddenly visible.
The reported timeline began on Oct. 4, 2026, when Hurts was struck on the calf by a cleat during the Eagles' game against the Los Angeles Rams. An initial clot in the calf was found during the team's trip to London, yet he still played the following Sunday against Jacksonville. Further testing during the week of Oct. 19 revealed more extensive clotting, and public statements were upgraded from superficial venous thrombosis in the calf to DVT with clots in both lungs. This progression from a limited calf finding to a more serious diagnosis is what turned a sports story into a broader medical news event.
Deep vein thrombosis is a condition in which a blood clot forms in a deep vein, most often in the leg or thigh, and it can partially or completely block blood flow. The main danger is that part of the clot can break loose and travel through the bloodstream to the lungs, where it becomes a pulmonary embolism. A pulmonary embolism is the blocked-artery event that makes DVT potentially life-threatening rather than just painful. This link between a leg clot and a lung clot is the reason doctors treat DVT seriously even when symptoms seem mild.
Doctors quoted in coverage note that DVT red flags include one-sided leg pain or swelling, since clots usually affect just one limb. A pulmonary embolism can cause unexplained shortness of breath, chest pain, coughing up blood, or fainting, according to Time.com. These symptoms are not proof of a clot on their own, and they overlap with many other conditions, so they are described as reasons to seek medical assessment rather than as a diagnosis. The practical message is that sudden one-sided leg swelling or new breathing difficulty deserves prompt medical attention.
The standard treatment for DVT and pulmonary embolism is anticoagulation, often called blood thinners, which reduce the blood's ability to form new clots and help stop existing ones from growing. Time.com notes that treatment generally lasts at least three months, and doctors quoted in the coverage said they "would not let an athlete play on blood thinners" because of bleeding risk from contact. Hurts is being treated with anticoagulation only, without reported surgery, according to statements from the team and his agent. Recovery timelines vary by patient and by the extent of clotting, so the three-month figure is an expectation for this case rather than a universal rule.
A professional football player on blood thinners faces a direct conflict between clotting risk and bleeding risk: the medication that prevents clots also makes collisions and internal injuries more dangerous. For that reason, the reported plan keeps Hurts out of contact activities, which effectively ends his 2026 season. NFL.com reported he is expected to miss the remainder of the season. This is a medical and safety decision, not a performance judgment, and it illustrates how anticoagulation can temporarily change what a patient is able to do.
Venous thromboembolism, or VTE, is the umbrella term for DVT and pulmonary embolism together. The American Vein & Lymphatic Society estimates 300,000 to 600,000 DVT cases a year in the United States, and the CDC attributes 60,000 to 100,000 deaths annually to related complications, as cited in coverage of the Hurts case. These figures are estimates from public health bodies and vary by source and year. They matter because they show that the condition driving the search trend is common, not exotic.
On Oct. 19, 2026, a study published in The Lancet Obstetrics, Gynaecology, & Women's Health added scientific interest to the same news cycle. The study followed more than 3 million women aged 15 to 49 using hormonal contraceptives across Denmark, Norway, Spain, and the United Kingdom between 2014 and 2024. It examined whether NSAIDs, a common class of painkillers, were linked to VTE risk. Because it appeared the same day as the Hurts news, it amplified the online conversation.
The study found that VTE risk was already elevated in the two weeks before women started an NSAID, peaked on the day they began taking it, and stayed above baseline after they stopped. Risk also rose with acetaminophen, which researchers used as a negative control because it is not expected to affect clotting. That pattern suggests the underlying condition prompting the painkiller, such as an infection or inflammation, may drive much of the risk rather than the drug itself. The authors caution that a direct NSAID effect cannot be ruled out.
An observational study follows people and records what happens without assigning treatments, so it can show associations but not prove cause and effect. The negative-control finding with acetaminophen is a key clue: when a drug not thought to affect clotting shows the same risk pattern, researchers suspect the illness being treated is a confounder. A confounder is a separate factor linked to both the exposure and the outcome. The authors' cautious wording reflects this limit rather than dismissing the finding.
Related evidence comes from a U.S. Women's Health Study cohort of 39,876 women covering 1993 to 2012. That analysis found NSAID initiation raised VTE risk compared with non-use, with a hazard ratio of 1.5 overall and 2.0 for coxibs, a subgroup of NSAIDs. However, the association was null or diminished when compared with acetaminophen initiation, echoing the newer study's pattern. Together these findings suggest that any NSAID-related clotting signal is entangled with the reason the painkiller was taken.
A different concern appears when NSAIDs are combined with anticoagulants. Research in the European Heart Journal found that internal bleeding risk was 2.09 times higher when people on anticoagulants also took an NSAID, according to a press release from the European Society of Cardiology. This is directly relevant to patients like Hurts who are on blood thinners. It does not mean every combination causes bleeding, but it is a reason such combinations are managed by clinicians rather than self-prescribed.
Beyond the headlines, medical circles were discussing the PRAGUE-26 trial results on catheter-directed thrombolysis, a technique that delivers clot-dissolving medication directly to the clot through a catheter. New EUHASS data suggested similar thrombosis rates for FVIII and FIX concentrates, which are clotting-factor products used in hemophilia care. The first Global Burden of Disease estimates to include venous thromboembolism reported roughly 1.6 million or more pulmonary embolism cases and 2.5 million or more DVT cases a year, according to thrombosis.org. These items are specialist-level context and are separate from the sports news.
Athletes are not immune to clots, and the reported sequence in this case began with a direct blow to the calf from a cleat. Trauma can injure a vessel and trigger clot formation, and long-distance travel, such as the team's London trip, is another recognized risk factor for leg clots. Prolonged immobility during travel slows blood flow in the legs, which is one mechanism behind travel-related DVT. This combination of impact injury and travel is a plausible explanation reported in coverage, not a confirmed cause.
Diagnosis typically starts with symptoms and a physical exam, followed by imaging such as an ultrasound of the leg veins for suspected DVT. For suspected pulmonary embolism, doctors may use a CT scan of the chest or other lung imaging. Blood tests can support the assessment but are not used alone to confirm a clot. In Hurts's case, the reported progression from a calf finding to a full DVT and lung clot diagnosis reflects this kind of stepwise testing.
Risk factors for VTE include recent surgery, prolonged immobility, cancer, pregnancy and the postpartum period, hormonal contraceptive use, and a personal or family history of clots. Older age and smoking also raise risk. This is why a clot in a young, fit professional athlete attracts attention: it shows that risk factors can combine in unexpected ways. The presence of a risk factor does not mean a clot will occur, and the absence of known risk factors does not rule one out.
The search spike is sports-driven, but the useful takeaway is medical awareness. One-sided leg pain or swelling and new unexplained breathing difficulty are symptoms worth having checked, according to the doctors quoted in coverage. Anticoagulation is an effective treatment for many patients, but it requires medical supervision and affects what activities are safe. Anyone with symptoms or concerns should speak to a clinician rather than draw conclusions from a news story.
Hormonal contraceptives are themselves a known risk factor for VTE, which is why a study focusing on women using them drew attention. The new research suggests that when these women take an NSAID, the illness driving the painkiller may explain much of the observed risk increase. That does not mean the combination is safe for everyone, and the authors explicitly note a direct drug effect cannot be excluded. Women with questions about painkillers while on hormonal contraception should raise them with a pharmacist or prescriber.
Several things remain unresolved in the reporting. The exact cause of Hurts's clotting has not been publicly confirmed, and the reported timeline links it to a calf impact without proving causation. The NSAID study is observational, so it cannot establish that painkillers cause clots, and its authors flag that limitation themselves. The specialist items, such as PRAGUE-26 and the GBD estimates, are early or summary findings that may be refined. Readers should treat each claim according to the strength of the evidence behind it.
The spike in searches for "blood clot" came primarily from a star quarterback's season-ending diagnosis of DVT and bilateral pulmonary emboli, announced on Oct. 19, 2026. A large Lancet study on NSAIDs and hormonal contraceptives, published the same day, added a scientific dimension to the same news cycle. Together they pushed a common but under-discussed condition into public view. The practical result is greater awareness of symptoms, treatment, and the limits of what the current evidence can say.
